ATE469646T1 - Pyrazolo-heteroaryl-verbindungen zur behandlung tnf-alpha- und il-1-vermittelter krankheiten - Google Patents

Pyrazolo-heteroaryl-verbindungen zur behandlung tnf-alpha- und il-1-vermittelter krankheiten

Info

Publication number: ATE469646T1
Authority: AT; Austria
Prior art keywords: alpha; tnf; pyrazolo; treatment; mediated diseases
Prior art date: 2004-12-16

Application number

AT05822740T

Other languages

English (en)

Inventor

Laszlo Revesz

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-16

Filing date

2005-12-14

Publication date

2010-06-15

2005-12-14 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2010-06-15 Application granted granted Critical

2010-06-15 Publication of ATE469646T1 publication Critical patent/ATE469646T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 2
201000010099 disease Diseases 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
102000000589 Interleukin-1 Human genes 0.000 abstract 1
108010002352 Interleukin-1 Proteins 0.000 abstract 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Epidemiology (AREA)
Child & Adolescent Psychology (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT05822740T 2004-12-16 2005-12-14 Pyrazolo-heteroaryl-verbindungen zur behandlung tnf-alpha- und il-1-vermittelter krankheiten ATE469646T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0427604.4A GB0427604D0 (en)	2004-12-16	2004-12-16	Organic compounds
PCT/EP2005/013453 WO2006063820A1 (en)	2004-12-16	2005-12-14	Pyrazolo-heteroaryl compounds useful to treat tnf-alpha and il-1 mediated diseases

Publications (1)

Publication Number	Publication Date
ATE469646T1 true ATE469646T1 (de)	2010-06-15

Family

ID=34090176

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05822740T ATE469646T1 (de)	2004-12-16	2005-12-14	Pyrazolo-heteroaryl-verbindungen zur behandlung tnf-alpha- und il-1-vermittelter krankheiten

Country Status (17)

Country	Link
US (1)	US20090258874A1 (de)
EP (1)	EP1833477B1 (de)
JP (1)	JP2008524141A (de)
KR (1)	KR20070087607A (de)
CN (1)	CN101076333A (de)
AT (1)	ATE469646T1 (de)
AU (1)	AU2005315849B2 (de)
BR (1)	BRPI0519337A2 (de)
CA (1)	CA2586543A1 (de)
DE (1)	DE602005021697D1 (de)
ES (1)	ES2345207T3 (de)
GB (1)	GB0427604D0 (de)
MX (1)	MX2007007218A (de)
PL (1)	PL1833477T3 (de)
PT (1)	PT1833477E (de)
RU (1)	RU2007126968A (de)
WO (1)	WO2006063820A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101011956B1 (ko) *	2005-08-25	2011-01-31	에프. 호프만-라 로슈 아게	Ｐ３８ｍαｐ 키나아제 저해제 및 이의 사용 방법
BRPI0615270A2 (pt) *	2005-08-25	2009-08-04	Hoffmann La Roche	pirazol fundido como inibidores de p38 map cinase
US20120232062A1 (en) *	2009-10-20	2012-09-13	Eiger Biopharmaceuticals, Inc.	Azaindazoles to treat flaviviridae virus infection
US8362023B2 (en)	2011-01-19	2013-01-29	Hoffmann-La Roche Inc.	Pyrazolo pyrimidines
US11466017B2 (en)	2011-03-10	2022-10-11	Board Of Regents, The University Of Texas System	Heterocyclic inhibitors of PTPN11
WO2013017479A1 (en)	2011-07-29	2013-02-07	Cellzome Limited	Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017480A1 (en)	2011-07-29	2013-02-07	Cellzome Limited	Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
US20140323504A1 (en)	2011-09-20	2014-10-30	Cellzome Limited	Pyrazolo[4,3-c]Pyridine Derivatives As Kinase Inhibitors
WO2014113942A1 (en) *	2013-01-23	2014-07-31	Merck Sharp & Dohme Corp.	Btk inhibitors
JP7044375B2 (ja)	2016-05-31	2022-03-30	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	Ｐｔｐｎ１１の複素環式阻害剤
CN112313232B (zh)	2018-05-02	2024-03-08	Jw中外制药公司	新型杂环衍生物
JP7297871B2 (ja)	2018-05-02	2023-06-26	ナビールファーマ，インコーポレイティド	Ｐｔｐｎ１１の置換されたヘテロ環式インヒビター
WO2020033828A1 (en)	2018-08-10	2020-02-13	Board Of Regents, The University Of Texas System	6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
KR20230112685A (ko) *	2020-11-25	2023-07-27	르네오 파마슈티컬스, 인크.	Ppar-델타 작용제의 제조 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2309206T3 (es) *	2001-10-02	2008-12-16	Smithkline Beecham Corporation	Compuestos quimicos.
RU2301233C2 (ru) *	2002-03-07	2007-06-20	Ф.Хоффманн-Ля Рош Аг	Бициклические пиридины и пиримидины в качестве ингибиторов киназы р38
TW200400034A (en) *	2002-05-20	2004-01-01	Bristol Myers Squibb Co	Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
NZ541836A (en) *	2003-02-27	2008-12-24	Palau Pharma Sa	Pyrazolopyridine derivatives
KR100844864B1 (ko) *	2004-02-27	2008-07-09	에프. 호프만-라 로슈 아게	헤테로아릴-융합 피라졸로 유도체
JP2007523938A (ja) *	2004-02-27	2007-08-23	エフ．ホフマン−ラ　ロシュ　アーゲー	ピラゾールの縮合誘導体

2004
- 2004-12-16 GB GBGB0427604.4A patent/GB0427604D0/en not_active Ceased
2005
- 2005-12-14 DE DE602005021697T patent/DE602005021697D1/de not_active Expired - Lifetime
- 2005-12-14 PT PT05822740T patent/PT1833477E/pt unknown
- 2005-12-14 MX MX2007007218A patent/MX2007007218A/es not_active Application Discontinuation
- 2005-12-14 WO PCT/EP2005/013453 patent/WO2006063820A1/en not_active Ceased
- 2005-12-14 US US11/721,822 patent/US20090258874A1/en not_active Abandoned
- 2005-12-14 EP EP05822740A patent/EP1833477B1/de not_active Expired - Lifetime
- 2005-12-14 BR BRPI0519337-0A patent/BRPI0519337A2/pt not_active IP Right Cessation
- 2005-12-14 RU RU2007126968/04A patent/RU2007126968A/ru not_active Application Discontinuation
- 2005-12-14 KR KR1020077013508A patent/KR20070087607A/ko not_active Withdrawn
- 2005-12-14 AU AU2005315849A patent/AU2005315849B2/en not_active Ceased
- 2005-12-14 CA CA002586543A patent/CA2586543A1/en not_active Abandoned
- 2005-12-14 AT AT05822740T patent/ATE469646T1/de not_active IP Right Cessation
- 2005-12-14 PL PL05822740T patent/PL1833477T3/pl unknown
- 2005-12-14 ES ES05822740T patent/ES2345207T3/es not_active Expired - Lifetime
- 2005-12-14 JP JP2007545941A patent/JP2008524141A/ja active Pending
- 2005-12-14 CN CNA2005800426060A patent/CN101076333A/zh active Pending

Also Published As

Publication number	Publication date
MX2007007218A (es)	2007-08-14
KR20070087607A (ko)	2007-08-28
EP1833477A1 (de)	2007-09-19
CN101076333A (zh)	2007-11-21
WO2006063820A1 (en)	2006-06-22
PL1833477T3 (pl)	2010-11-30
AU2005315849A1 (en)	2006-06-22
RU2007126968A (ru)	2009-01-27
EP1833477B1 (de)	2010-06-02
CA2586543A1 (en)	2006-06-22
JP2008524141A (ja)	2008-07-10
PT1833477E (pt)	2010-08-20
US20090258874A1 (en)	2009-10-15
ES2345207T3 (es)	2010-09-17
GB0427604D0 (en)	2005-01-19
DE602005021697D1 (de)	2010-07-15
BRPI0519337A2 (pt)	2009-01-20
AU2005315849B2 (en)	2009-05-28

Legal Events

Date

Code

Title

Description

2010-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1833477

Country of ref document: EP

2012-03-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
EA201170521A1 (ru)	2011-12-30	Новые соединения
MA32811B1 (fr)	2011-11-01	Nouveaux composés
DE502005010615D1 (de)	2011-01-13	Mittel zur behandlung von entzündlichen erkrankungen
ATE544748T1 (de)	2012-02-15	Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
EA201070422A1 (ru)	2010-12-30	Производные оксадиазола
EA200802054A1 (ru)	2009-04-28	Ингибиторы фермента
DE602005021697D1 (de)	2010-07-15	Pyrazolo-heteroaryl-verbindungen zur behandlung tnf-alpha- und il-1-vermittelter krankheiten
EA201100447A1 (ru)	2011-10-31	Органические соединения
MX2009013353A (es)	2010-07-06	Compuestos activadores de telomerasa y metodos para su uso.
EP2135858A4 (de)	2012-02-08	Zusammensetzung zur behandlung von infektionserkrankungen
EA201000100A1 (ru)	2010-08-30	Гетероциклические соединения, полезные в качестве ингибиторов mk2
DE602005025517D1 (de)	2011-02-03	Herstellung und anwendung von biphenyl-4-yl-carbonylaminosäurederivaten zur behandlung von obesitas
EA201071045A1 (ru)	2011-02-28	Соединения оксадиазоантрацена для лечения диабета
ATE502633T1 (de)	2011-04-15	Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
EA201301040A1 (ru)	2014-01-30	Гетероциклическое соединение и его применение
DE502004005033D1 (de)	2007-10-31	Substituierte 2-aminotetraline zur behandlung von depressionen
EA201001522A1 (ru)	2011-06-30	Новые p2x7r антагонисты и их применение
EA201100874A1 (ru)	2012-01-30	Соединения для лечения рака
EA201070442A1 (ru)	2010-10-29	НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ
DE502005008058D1 (de)	2009-10-15	Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
ATE447948T1 (de)	2009-11-15	Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
ATE501718T1 (de)	2011-04-15	Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
ATE464895T1 (de)	2010-05-15	Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen
ATE500253T1 (de)	2011-03-15	3-cyano-5-thiazaheteroaryl-dihydropyridine und ihre verwendung zur behandlung kardiovaskulärer erkrankungen
ATE432936T1 (de)	2009-06-15	Imidazotriazin verbindungen zur behandlung von krebserkrankungen